Anti-CGRP Migraine Drugs Cut Monthly Headache Days by Nearly Half in Catalan Cohort
A Catalan registry study of 5438 patients found anti-CGRP antibody treatment cut monthly migraine days by about 45 percent while spending surpassed 18 million euros.
A Catalan registry study of 5438 patients found anti-CGRP antibody treatment cut monthly migraine days by about 45 percent while spending surpassed 18 million euros.
Preventive care now may begin at four migraine days a month, with newer CGRP drugs joining older medicines as first-line options
CHICAGO — A monoclonal antibody that inhibits angiopoietin-like protein 4 was linked to triglyceride reduction at 12 weeks in adults with high triglycerides, researchers reported a...
The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China
NASHVILLE, Tenn. — Patients with Crohn’s disease achieved significantly higher clinical remission and endoscopic response rates at week 12 with subcutaneous risankizumab induction...
A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.
Argenx Anonymous (not verified) Thu, 11/05/2026 - 18:31 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor respo...
The FDA has expanded its approval of Skyrizi to include subcutaneous induction for adults with moderately to severely active Crohn’s disease.Risankizumab (Skyrizi, AbbVie) was appr...
By Pat AnsonImagine what it would be like to know – with over 90% accuracy – that you’re going to have a migraine tomorrow.You’d be able to plan ahead. Change your schedule. Get ex...
SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ded...
For millions of people living with IgG-mediated autoimmune diseases such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)...
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.